Efficacy and safety of taxane versus gemcitabine for advanced stage lung squamous cell carcinoma in global EHR-based retrospective cohorts: A pairwise propensity score-matched comparison

Lung, Respiratory and Thoracic Cancer

Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation

Adv Ther

Chopra D, Lan Z, Waterhouse DM, Wolf J, Felip E, Moradian H, Karim N, Obiozor C, Stollenwerk B

doi: 10.1007/s12325-025-03259-8

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of consolidative thoracic radiotherapy for Extensive-Stage Small-Cell lung cancer in the era of immunotherapy: A Real-World study

Lung Cancer

Zhang C, Wang W, Bi N, Wang J, Liu W, Zhang T, Wang X, Xiao Z, Lv J, Feng Q, Deng L, Zhou Z

doi: 10.1016/j.lungcan.2025.108758

Lung, Respiratory and Thoracic Cancer

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

Lung Cancer

Tambo Y, Sone T, Nishi K, Shibata K, Kita T, Araya T, Shirasaki H, Shimizu T, Yoneda T, Matsuoka H, Nanjo S, Koba H, Terada N, Ueda T, Nomura S, Murase Y, Yano S

doi: 10.1016/j.lungcan.2025.108422

Lung, Respiratory and Thoracic Cancer

Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials

J Thorac Oncol

Herbst RS, Prizant H, Ruderman D, Conway J, Shamshoian J, Koeppen H, Zou W, de Marinis F, Giaccone G, Jassem J, Spigel DR, Socinski MA, Reck M, Molinero L, Ballinger M, Shames D, Griffin M, Yu L, Agrawal N, Beck A, Wapinski I, Hennek S, Giltnane J, Srivastava MK

doi: 10.1016/j.jtho.2025.07.131

Lung, Respiratory and Thoracic Cancer

Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis

Lung Cancer

Girard N, Han JY, Soo RA, Wang K, Tang W, Nikolaidis GF, Tasoulas A, Barouma I, Castro JC, Yang Z, Chaudhary T, Zhan L

doi: 10.1016/j.lungcan.2025.108450

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hultén A, Greystoke A

doi: 10.1016/j.lungcan.2025.108548

Lung, Respiratory and Thoracic Cancer

Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model

Lung Cancer

Vaes RDW, Cortiula F, Lyu S, Hiltermann TJN, Houben R, Degens J, Hendriks LEL, Ruysscher D

doi: 10.1016/j.lungcan.2025.108541

Lung, Respiratory and Thoracic Cancer

A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer

Eur J Cancer

Byun JY, Kim J, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Kim JH, Lee EK, Jung HA

doi: 10.1016/j.ejca.2025.115805

Leukemia

Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

Leukemia

Alfonso-Pierola A, Martinez-Cuadrón D, Rodríguez-Veiga R, Gil C, Martínez-Sánchez P, Bernal T, Benavente C, Romero-Riquelme MA, Serrano-Lopez J, Bergua JM, García-Boyero R, Tormo M, Herrera P, Sossa-Melo CL, Pérez-Simon JA, Rodríguez-Medina C, Bass-Maturana MF, López-Lorenzo JL, Algarra-Algarra L, Vidriales-Vicente B, Pérez-Encinas M, Barrios-García M, Vives S, Sayas-Lloris MJ, Capurro M, Hidalgo S, Olave M, Cuervo-Lozada D, Lavilla-Rubira E, Casado F, Mena-Durán A, Valero-Nuñez M, Casado-Calderón S, Balerdi A, Torres V, Fernández R, Noriega V, Stevenazzi M, Labrador J, León-Maldonado P, de Rueda-Ciller B, Arce-Fernández O, Amigo ML, Raposo-Puglia JÁ, Solé M, Boluda B, Ayala R, Barragán E, Montesinos P, PETHEMA Group

doi: 10.1038/s41375-025-02744-x

Related content

Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation

Efficacy and safety of consolidative thoracic radiotherapy for Extensive-Stage Small-Cell lung cancer in the era of immunotherapy: A Real-World study

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials

Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis

Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study

Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model

A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer

Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry